Curative efficacy of purified serine protease inhibitor PTF3 from potato tuber in experimental visceral leishmaniasis

Int Immunopharmacol. 2020 Aug:85:106623. doi: 10.1016/j.intimp.2020.106623. Epub 2020 Jun 5.

Abstract

To overcome the drug toxicity and frequent resistance of parasites against the conventional drugs for the healing of human visceral leishmaniasis, innovative plant derived antileishmanial components are very imperative. Fuelled by the complications of clinically available antileishmanial drugs, a novel potato serine protease inhibitor was identified with its efficacy on experimental visceral leishmaniasis (VL). The serine protease inhibitors from potato tuber extract (PTEx) bearing molecular mass of 39 kDa (PTF1), 23 kDa (PTF2) and 17 kDa (PTF3) were purified and identified. Among them, PTF3 was selected as the most active inhibitor (IC50 143.5 ± 2.4 µg/ml) regarding its antileishmanial property. Again, intracellular amastigote load was reduced upto 83.1 ± 1.7% in pre-treated parasite and 88.5 ± 0.5% in in vivo model with effective dose of PTF3. Protective immune response by PTF3 was noted with increased production of antimicrobial substances and up-regulation of pro-inflammatory cytokines. Therapeutic potency of PTF3 is also followed by 80% survival in infected hamster. The peptide mass fingerprint (MALDI-TOF) results showed similarity of PTF3 with serine protease inhibitors database. Altogether, these results strongly propose the effectiveness of PTF3 as potent immunomodulatory therapeutics for controlling VL.

Keywords: Leishmania donovani; Nitric oxide (NO); Potato tuber fraction (PTF); Pro-inflammatory cytokine; Reactive oxgen species (ROS); Serine protease inhibitors.

MeSH terms

  • Animals
  • Antiprotozoal Agents / chemistry
  • Antiprotozoal Agents / isolation & purification
  • Antiprotozoal Agents / pharmacology*
  • Antiprotozoal Agents / therapeutic use
  • Cricetinae
  • Cytokines / metabolism
  • Disease Models, Animal
  • Immunomodulation / drug effects
  • Leishmania donovani / drug effects
  • Leishmania donovani / growth & development
  • Leishmania donovani / ultrastructure
  • Leishmaniasis, Visceral / drug therapy*
  • Liver / parasitology
  • Mice, Inbred BALB C
  • Models, Animal
  • NF-kappa B p50 Subunit / metabolism
  • Nitric Oxide / metabolism
  • Nitric Oxide Synthase Type II / metabolism
  • Phytotherapy / methods*
  • Plant Extracts / chemistry
  • Plant Extracts / isolation & purification
  • Plant Extracts / pharmacology
  • Plant Extracts / therapeutic use
  • Plant Tubers / chemistry*
  • Reactive Oxygen Species / metabolism
  • Serine Proteinase Inhibitors / chemistry
  • Serine Proteinase Inhibitors / isolation & purification
  • Serine Proteinase Inhibitors / pharmacology*
  • Serine Proteinase Inhibitors / therapeutic use
  • Solanum tuberosum / chemistry*
  • Spleen / immunology
  • Spleen / parasitology
  • Survival Analysis

Substances

  • Antiprotozoal Agents
  • Cytokines
  • NF-kappa B p50 Subunit
  • Plant Extracts
  • Reactive Oxygen Species
  • Serine Proteinase Inhibitors
  • Nfkb1 protein, mouse
  • Nitric Oxide
  • Nitric Oxide Synthase Type II
  • Nos2 protein, mouse